* If you want to update the article please login/register
Based on the unmet need in MPC, the high incidence of Ras mutations, and previous research combining PP +C+G in pts with MPC, we investigated the addition of AA to the regimen. MPC's main aim of the phase 1b was to determine the maximum tolerated dose of AA in combination with PP +C +G in pts with MPC. An imaging biomarker for response; correlation between peak plasma levels of AA and response to treatment; and changes in the number of circulating tumor stem cells and macrophage lineage changes were among the study's goals; and correlation between peak plasma concentrations of AA and response to therapy; and tumor immuno cell infiltration, stromal activation, stem call enumeration; and tumor cell infiltration, tumor cell infiltration, circulating tumor stem cell infiltration; and macrophage lineage These were the most common AEs related to study treatment: platelet count decrease, diarrhea, hypomagnesemia, dysgeusia, peripheral sensory neuropathy, nausea, vomiting, and hypokalemia. In all AA dosing cohorts, the majority of pts developed a brisk response to therapy. In all dose cohorts, AA did not appear to add toxicities compared to historical AE results of PP +C +G, and was well tolerated. However, none of the 56. 25 gm/m2 cohort met our target of elevated plasma AA levels of > 20 mM, so enrollment was suspended. Patients with newly diagnosed metastatic pancreatic cancer with high dose ascorbic acid + paclitaxel protein bound + cisplatin + gemcitabine are patients with previously untreated metastatic pancreatic cancer [abstract].
Source link: https://doi.org/10.1158/1538-7445.panca21-po-015
Abstract: In patients with metastatic pancreatic cancer patients, gemcitabine plus nab-paclitaxel has been shown to extend overall survival in comparison to GEM monotherapy. With GEM/nab, we found that sarcopenia may have increased the risk of chemotherapy involvement in pancreatic cancer patients treated with GEM/nab. Methods: At a northern Alberta cancer center from 2014-2017, a retrospective review of all patients who received GEM/nab as first-line therapy for metastatic pancreatic cancer was done. To determine skeletal muscle index, the L3 muscle surface area was determined on baseline CT scans and normalized for height. In sarcopenic versus non-sarcopenic patients, the incidence of DLT was significantly higher. Conclusion: sarcopenic patients treated with GEM/nab are significantly more likely to experience DLT, regardless of age, sex, BMI, and PS, regardless of age, gender, BMI, and PS. These results may have ramifications with reduced chemotherapy dosing in sarcopenic patients. [abstract]: Sarcopenia expects dose-limiting adverse outcomes in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel [abstract].
Source link: https://doi.org/10.1158/1538-7445.am2021-432
PURPOSE The optimal perioperative chemotherapy regimen for patients with nonmetastatic muscle-invasive bladder cancer is uncertain. GETUG-AFU V05 VESPER trial : progression-free survival at three years is reported at our primary end point. Patients underwent surgery, respectively; four hundred thirty-seven patients received the planned six cycles in the dd-MVAC arm; 60% of patients received four cycles in the GC arm; and after that, 91% and 90% of patients underwent surgery. Patients in the adjuvant group received six cycles in the dd-MVAC arm, and 81% of patients in the GC arm received four cycles in the GC arm. For all patients in the clinical trial, 3-year PFS was boosted in the dd-MVAC arm, but the report did not reach its primary end point; nevertheless, the dd-MVAC arm had a longer time to progress compared to its primary end point; nonetheless, the dd-MVAC arm had a significantly longer time to progress.
Source link: https://doi.org/10.1200/jco.21.02051
Background Pancreatic cancer is a risk factor that increases the risk of thromboembolism. With gemcitabine plus nab-paclitaxel, we investigated the possibility of early venous thromboembolism detection in patients with unresectable pancreatic cancer patients receiving first-line chemotherapy. We compared the patients with early detection of VTE with the others at the same time. At diagnosis, thirteen patients were diagnosed with VTE at diagnosis, and four patients were hospitalized after treatment began. The VTE group had worse OS and PFS than the VTE group, as shown by the VTE group. In multivariate experiments, although the outcomes in the VTE group were poorer, VTE was identified as a statistically significant independent predictor of OS. Early VTE testing for patients with UR-MPC is a predictor of a poor prognosis in UR-MPC patients receiving GnP as first-line chemotherapy, according to the authors, so screening VTE for patients with UR-MPC is vital, even if patients are asymptomatic.
Source link: https://doi.org/10.1371/journal.pone.0264653
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions